[Treatment of spastic bronchitis with a new bronchospasmolytic agent].
D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy; D001986:Bronchial Spasm / Q000150:complications / Q000188:drug therapy*; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009921:Metaproterenol / Q000627:therapeutic use*; D008875:Middle Aged; D009784:Occupational Diseases / Q000188:drug therapy; D010276:Parasympatholytics / Q000627:therapeutic use*; D010636:Phenols / Q000627:therapeutic use; D012129:Respiratory Function Tests; D012829:Silicosis / Q000188:drug therapy
D001993:Bronchodilator Agents; D010276:Parasympatholytics; D010636:Phenols; D009921:Metaproterenol
Zur Behandlung der spastischen Bronchitis mit einem neuen Bronchospasmolytikum.